APO Research
Talk to an analyst

APO RESEARCH · REPORT

Proliferative Vitreoretinopathy (PVR) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchProliferative Vitreoretinopathy (PVR) Therapeutics Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Proliferative Vitreoretinopathy (PVR) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics include Novartis AG, RXi Pharmaceuticals Corp and Promedior Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Proliferative Vitreoretinopathy (PVR) Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Proliferative Vitreoretinopathy (PVR) Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Proliferative Vitreoretinopathy (PVR) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Proliferative Vitreoretinopathy (PVR) Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Company

Novartis AG

RXi Pharmaceuticals Corp

Promedior Inc

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Type

PRM-167

XOMA-089

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Application

Clinic

Hospital

ASCs

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proliferative Vitreoretinopathy (PVR) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proliferative Vitreoretinopathy (PVR) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Proliferative Vitreoretinopathy (PVR) Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PRM-167 Major Manufacturers Table 3. XOMA-089 Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Clinic Major Manufacturers Table 7. Hospital Major Manufacturers Table 8. ASCs Major Manufacturers Table 9. Others Major Manufacturers Table 10. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends Table 11. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers Table 12. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges Table 13. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints Table 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2021-2026) Table 18. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2027-2032) Table 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2026) & (k units) Table 21. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2027-2032) & (k units) Table 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2021-2026) Table 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2027-2032) Table 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2021-2026) Table 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers, Product Type & Application Table 32. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Proliferative Vitreoretinopathy (PVR) Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2026) Table 39. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2027-2032) Table 40. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 42. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 43. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2026) Table 44. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2027-2032) Table 45. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2026) & (US$/unit) Table 46. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2027-2032) & (US$/unit) Table 47. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2026) Table 51. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2027-2032) Table 52. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 54. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 55. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2026) Table 56. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2027-2032) Table 57. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2026) & (US$/unit) Table 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2027-2032) & (US$/unit) Table 59. Novartis AG Company Information Table 60. Novartis AG Business Overview Table 61. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 63. Novartis AG Recent Development Table 64. RXi Pharmaceuticals Corp Company Information Table 65. RXi Pharmaceuticals Corp Business Overview Table 66. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 68. RXi Pharmaceuticals Corp Recent Development Table 69. Promedior Inc Company Information Table 70. Promedior Inc Business Overview Table 71. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 73. Promedior Inc Recent Development Table 74. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 75. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 76. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 77. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 78. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 79. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 80. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 83. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 84. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 85. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 86. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 88. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 89. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 90. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 91. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 92. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 93. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 94. United States Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 95. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 96. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 97. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 100. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 101. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 102. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 103. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 106. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 107. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 108. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 109. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 113. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 114. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 115. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 116. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 117. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 118. France Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 119. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 120. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 121. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 122. Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 123. Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 124. Switzerland Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 125. Sweden Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 126. Poland Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 127. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 128. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 129. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 130. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 131. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 132. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 133. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 134. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 135. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 136. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 137. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 138. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 139. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 140. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 141. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 142. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 143. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 144. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 145. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 146. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 148. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 149. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 150. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 151. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 155. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 156. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 157. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 158. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 159. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 160. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 161. India Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 162. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 163. Taiwan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 164. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 165. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 166. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 167. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2026) & (k units) Table 168. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2027-2032) & (k units) Table 169. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 170. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 171. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 172. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 173. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2026) & (k units) Table 174. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2027-2032) & (k units) Table 175. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 176. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 177. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 179. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 180. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 181. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 182. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 183. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 184. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 185. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 186. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 187. Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 188. Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 189. Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 190. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 191. Israel Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 192. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 193. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 194. Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 195. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors List Table 199. Proliferative Vitreoretinopathy (PVR) Therapeutics Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Image Figure 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. PRM-167 Image Figure 5. XOMA-089 Image Figure 6. Others Image Figure 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Clinic Image Figure 10. Hospital Image Figure 11. ASCs Image Figure 12. Others Image Figure 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2021-2032) Figure 18. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (2021-2032) & (k units) Figure 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales YoY (2021-2032) & (k units) Figure 22. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales YoY (2021-2032) & (k units) Figure 23. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Proliferative Vitreoretinopathy (PVR) Therapeutics Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales YoY (2021-2032) & (k units) Figure 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2032) Figure 32. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2032) Figure 35. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2032) Figure 38. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2032) Figure 41. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2021-2032) Figure 42. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2021-2032) Figure 43. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Application (2021-2032) Figure 44. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2021-2032) Figure 45. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country (2021-2032) Figure 46. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Country (2021-2032) Figure 47. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2021-2032) Figure 48. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2021-2032) Figure 49. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Application (2021-2032) Figure 50. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2021-2032) Figure 51. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country (2021-2032) Figure 52. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Country (2021-2032) Figure 53. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2021-2032) Figure 54. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2021-2032) Figure 55. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Application (2021-2032) Figure 56. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2021-2032) Figure 57. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2021-2032) Figure 58. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2021-2032) Figure 59. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Application (2021-2032) Figure 60. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2021-2032) Figure 61. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country (2021-2032) Figure 62. Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Country (2021-2032) Figure 63. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2021-2032) Figure 64. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2021-2032) Figure 65. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Application (2021-2032) Figure 66. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2021-2032) Figure 67. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Country (2021-2032) Figure 68. SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Country (2021-2032) Figure 69. Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • PRM-167
  • XOMA-089
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
  • Others
Companies covered
  • Novartis AG
  • RXi Pharmaceuticals Corp
  • Promedior Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
  3. 1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PRM-167
  5. 1.2.3 XOMA-089
  6. 1.2.4 Others
  7. 1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
  8. 1.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinic
  10. 1.3.3 Hospital
  11. 1.3.4 ASCs
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Dynamics
  1. 2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
  2. 2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers
  3. 2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
  3. 3.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2021-2026)
  5. 3.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2027-2032)
  6. 3.2.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region
  9. 3.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2026)
  11. 3.4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2027-2032)
  12. 3.4.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers
  2. 4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers
  6. 4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers, Product Type & Application
  13. 4.7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market CR5 and HHI
  16. 4.8.2 2025 Proliferative Vitreoretinopathy (PVR) Therapeutics Tier 1, Tier 2, and Tier 3
5 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
  1. 5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type
  2. 5.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type
  6. 5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2021-2032)
  9. 5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type
6 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
  1. 6.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application
  2. 6.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application
  6. 6.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2021-2032)
  9. 6.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 RXi Pharmaceuticals Corp
  8. 7.2.1 RXi Pharmaceuticals Corp Company Information
  9. 7.2.2 RXi Pharmaceuticals Corp Business Overview
  10. 7.2.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  12. 7.2.5 RXi Pharmaceuticals Corp Recent Developments
  13. 7.3 Promedior Inc
  14. 7.3.1 Promedior Inc Company Information
  15. 7.3.2 Promedior Inc Business Overview
  16. 7.3.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  18. 7.3.5 Promedior Inc Recent Developments
8 North America
  1. 8.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
  2. 8.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  3. 8.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  4. 8.1.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2032)
  5. 8.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
  6. 8.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  7. 8.2.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  8. 8.2.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2032)
  9. 8.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
  10. 8.3.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
  2. 9.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  3. 9.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  4. 9.1.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2032)
  5. 9.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
  6. 9.2.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  7. 9.2.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  8. 9.2.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2032)
  9. 9.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
  10. 9.3.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
  2. 10.1.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  3. 10.1.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  4. 10.1.3 China Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2032)
  5. 10.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
  6. 10.2.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  7. 10.2.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  8. 10.2.3 China Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
  2. 11.1.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  3. 11.1.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  4. 11.1.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2032)
  5. 11.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
  6. 11.2.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  7. 11.2.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  8. 11.2.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2032)
  9. 11.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
  10. 11.3.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
  2. 12.1.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2021-2032)
  5. 12.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
  6. 12.2.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2021-2032)
  9. 12.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
  10. 12.3.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Analysis
  2. 13.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process
  6. 13.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
  9. 13.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst